RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $50

Benzinga Newsdesk www.benzinga.com Negative 93.9%

Neg 93.9% Neu 0% Pos 0%

RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $51 to $50.